Market Cap | 43.17M | P/E | - | EPS this Y | 12.30% | Ern Qtrly Grth | - |
Income | -50.46M | Forward P/E | -0.93 | EPS next Y | 20.60% | 50D Avg Chg | 1.00% |
Sales | 24.71M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -29.00% |
Dividend | N/A | Price/Book | 0.28 | EPS next 5Y | - | 52W High Chg | -78.00% |
Recommedations | 1.50 | Quick Ratio | 4.56 | Shares Outstanding | 37.60M | 52W Low Chg | 23.00% |
Insider Own | 8.56% | ROA | -24.41% | Shares Float | 9.15M | Beta | 1.12 |
Inst Own | 60.38% | ROE | -43.09% | Shares Shorted/Prior | 70.25K/79.62K | Price | 1.02 |
Gross Margin | -14.22% | Profit Margin | -204.22% | Avg. Volume | 49,069 | Target Price | 8.00 |
Oper. Margin | -202.15% | Earnings Date | Aug 2 | Volume | 13,675 | Change | 2.74% |
Rapid Micro Biosystems, Inc., a life sciences technology company, provides products for the detection of microbial contamination in the manufacture of pharmaceutical, medical devices, and personal care products in the United States, Germany, Switzerland, Japan, and internationally. The company offers Growth Direct platform, which includes Growth Direct system, proprietary consumables, lab information management system connection software, and customer support and validation services. Its platform automates and modernizes the manual microbial quality control (MQC) testing workflows for therapeutic modalities, such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company also provides onsite technical training services. Its solutions are used in environmental monitoring, water, bioburden, and sterility release testing applications. In addition, the company offers RMBNucleus software for the Growth Direct system; RMBNucleus Mold Alarm signals at the first sign of mold detection; RMBNucleus Central Manager portal streamlines coordination of multiple instruments; and Growth Direct LIMS connection software. Rapid Micro Biosystems, Inc. was formerly known as Genomic Profiling Systems, Inc. and changed its name to Rapid Micro Biosystems, Inc. in January 2007. The company was incorporated in 2006 and is headquartered in Lowell, Massachusetts.
Morgan Stanley | Equal-Weight | Mar 7, 23 |
JP Morgan | Neutral | Aug 16, 22 |
Morgan Stanley | Equal-Weight | May 11, 22 |
Morgan Stanley | Equal-Weight | Mar 7, 22 |
Morgan Stanley | Equal-Weight | Feb 15, 22 |
Morgan Stanley | Equal-Weight | Nov 15, 21 |
Cowen & Co. | Outperform | Aug 9, 21 |
Morgan Stanley | Equal-Weight | Aug 9, 21 |
Stifel | Buy | Aug 9, 21 |
Insider Trades | Relationship | Date | Transactions | Cost($) | #Shares | Value($) | #Share Own | SEC Form 4 |
---|---|---|---|---|---|---|---|---|
WIRTJES SEAN M | CHIEF FINANCIAL OFFI.. CHIEF FINANCIAL OFFICER | Sep 06 | Buy | 0.9894 | 10,000 | 9,894 | 285,651 | 09/08/23 |
Spignesi Robert G. Jr. | PRESIDENT AND CEO PRESIDENT AND CEO | Aug 15 | Buy | 0.9744 | 20,000 | 19,488 | 375,512 | 08/16/23 |
KENNEDY LEWIS MANAGEMENT LP | 10% Owner 10% Owner | Jun 02 | Buy | 4.83 | 60,100 | 290,283 | 2,904,490 | 06/06/22 |
KENNEDY LEWIS MANAGEMENT LP | 10% Owner 10% Owner | May 27 | Buy | 5.05 | 68,617 | 346,516 | 2,869,154 | 06/01/22 |
KENNEDY LEWIS MANAGEMENT LP | 10% Owner 10% Owner | May 25 | Buy | 4.63 | 49,883 | 230,958 | 2,828,810 | 05/26/22 |
KENNEDY LEWIS MANAGEMENT LP | 10% Owner 10% Owner | May 17 | Buy | 4.04 | 96,516 | 389,925 | 2,799,481 | 05/19/22 |
Spignesi Robert G. Jr. | President and CEO President and CEO | May 16 | Buy | 3.795 | 10,000 | 37,950 | 194,027 | 05/18/22 |
WIRTJES SEAN M | Chief Financial Offi.. Chief Financial Officer | Mar 17 | Option | 1.00 | 10,000 | 10,000 | 191,631 | 03/21/22 |
Spignesi Robert G. Jr. | President and CEO President and CEO | Mar 14 | Option | 1.00 | 35,000 | 35,000 | 184,027 | 03/15/22 |
LOWENSTEIN INESE | Director Director | Mar 10 | Buy | 6.95 | 10,000 | 69,500 | 10,000 | 03/14/22 |